Physician profile
Alan S Multz
NPI 1558430835
$3,834.51
in general payments reported to CMS, 2019-2025
11 companies · $66.07 in 2025
The $66.07 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $1,089 · 2021: $1,346 · 2022: $67.89 · 2023: $591 · 2025: $66.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $455 · Food and Beverage: $202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $455.00 |
| Food and Beverage | $202.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $950.00 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $787.50 | 2020-2023 | |
| Zoll Medical Corporation | $551.67 | 2019-2021 | |
| Becton, Dickinson and Company | $520.83 | 2019-2021 | |
| C. R. Bard, INC. & Subsidiaries | $373.33 | 2020 | |
| Novocure Gmbh | $291.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $174.02 | 2020-2023 | Xarelto |
| Pfizer INC. | $67.76 | 2022-2023 | |
| Abbott Laboratories | $66.07 | 2025 | Jot Dx |
| Alnylam Pharmaceuticals INC. | $27.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Multz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.